This case series study of 502 individuals found that, after adjusting for age and baseline AMD severity, compared with individuals with 2 risk alleles exclusively at CFH-CFHR5, the time to conversion to late-stage disease was shortest among carriers of 2 risk alleles at each of the ARMS2/HTRA1 and CFH-CFHR5 loci, followed by individuals with 2 risk alleles exclusively at ARMS2/HTRA1. This evidence concerns the gene CFH and age-related macular degeneration.